Glaukos (GKOS) 10-K 28 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Feb. 26, 2018	Jun. 30, 2017
Document and Entity Information
Entity Registrant Name	GLAUKOS Corp
Entity Central Index Key	1,192,448
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		34,740,886
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Public Float			$ 1,268

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 24,508	$ 6,494
Short-term investments	94,506	89,268
Accounts receivable, net	16,656	14,305
Inventory, net	11,222	6,844
Prepaid expenses and other current assets	2,568	3,032
Restricted cash		80
Total current assets	149,460	120,023
Property and equipment, net	11,794	7,593
Intangible asset, net	3,147	6,567
Deferred tax asset, net	235
Deposits and other assets	1,200	188
Total assets	165,836	134,371
Current liabilities:
Accounts payable	6,244	2,967
Accrued liabilities	20,449	13,911
Deferred rent	95	60
Total current liabilities	26,788	16,938
Other liabilities	846	159
Total liabilities	27,634	17,097
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value; 150,000 shares authorized, 34,647 and 33,971 shares issued and 34,619 and 33,943 shares outstanding at December 31, 2017 and 2016, respectively	35	34
Additional paid-in capital	331,073	308,815
Accumulated other comprehensive (loss) income	(591)	648
Accumulated deficit	(192,183)	(192,091)
Less treasury stock (28 shares as of December 31, 2017 and 2016)	(132)	(132)
Total stockholders' equity	138,202	117,274
Total liabilities and stockholders' equity	$ 165,836	$ 134,371

CONSOLIDATED BALANCE SHEETS (PA

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares shares in Thousands	Dec. 31, 2017	Dec. 31, 2016
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000	150,000
Common stock, shares issued	34,647	33,971
Common stock, shares outstanding	34,619	33,943
Treasury stock, shares	28	28

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
CONSOLIDATED STATEMENTS OF OPERATIONS
Net sales	$ 159,254	$ 114,397	$ 71,700
Cost of sales	21,050	16,177	12,988
Gross profit	138,204	98,220	58,712
Operating expenses:
Selling, general and administrative	96,260	64,756	43,961
In-process research and development	5,320
Research and development	38,905	29,223	25,047
Total operating expenses	140,485	93,979	69,008
(Loss) income from operations	(2,281)	4,241	(10,296)
Other income (expense), net
Interest and other income	2,326	889	82
Loss on deconsolidation of DOSE			(25,685)
Loss on extinguishment of debt			(195)
Interest and other expense, net	(44)	(608)	(1,062)
Change in fair value of stock warrant liability		43	(1,132)
Total other income (expense), net	2,282	324	(27,992)
Income (loss) before taxes	1	4,565	(38,288)
Provision for income taxes	93	43	33
Net (loss) income	(92)	4,522	(38,321)
Net loss attributable to noncontrolling interest			(1,080)
Net (loss) income attributable to Glaukos Corporation stockholders	$ (92)	$ 4,522	$ (37,241)
Basic net (loss) income per share, attributable to Glaukos Corporation stockholders	$ 0	$ 0.14	$ (2.13)
Diluted net (loss) income per share, attributable to Glaukos Corporation stockholders	$ 0	$ 0.12	$ (2.13)
Weighted average shares used to compute basic net (loss) income per share attributable to Glaukos Corporation stockholders	34,381	32,928	17,474
Weighted average shares used to compute diluted net (loss) income per share attributable to Glaukos Corporation stockholders	34,381	36,459	17,474

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
Net (loss) income	$ (92)	$ 4,522	$ (38,321)
Other comprehensive (loss) income:
Foreign currency translation (loss) gain	(1,115)	542	155
Unrealized (loss) gain on short-term investments, net of tax	(124)	55	(148)
Other comprehensive (loss) income	(1,239)	597	7
Total comprehensive (loss) income	(1,331)	5,119	(38,314)
Comprehensive loss attributable to noncontrolling interest			(1,080)
Total comprehensive (loss) income	$ (1,331)	$ 5,119	$ (37,234)

CONSOLIDATED STATEMENTS OF CONV

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in-Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Treasury Stock	Noncontrolling Interest	Total
Balance at Dec. 31, 2014	$ 6	$ 8,155	$ 44	$ (159,372)	$ (132)	$ (9,605)	$ (160,904)
Balance (in shares) at Dec. 31, 2014	2,470				(28)
Stockholders' Deficit
Conversion of preferred stock into common stock	$ 17	159,060					159,077
Conversion of preferred stock into common stock (in shares)	21,736
Issuance of common stock in initial public offering	$ 7	113,582					113,589
Issuance of common stock in initial public offering (in shares)	6,900
Common stock issued under stock plans	$ 2	2,979					2,981
Common stock issued under stock plans (in shares)	1,097
Exercise of common stock warrant		188					188
Exercise of common stock warrant (in shares)	6
Share-based compensation		7,889					7,889
Other comprehensive income			7				7
Deconsolidation of DOSE						(10,685)	(10,685)
Net (loss) income				(37,241)		$ (1,080)	(38,321)
Balance at Dec. 31, 2015	$ 32	291,853	51	(196,613)	$ (132)		95,191
Balance (in shares) at Dec. 31, 2015	32,209				(28)
Stockholders' Deficit
Common stock issued under stock plans	$ 2	8,064					8,066
Common stock issued under stock plans (in shares)	1,756
Exercise of common stock warrant		112					112
Exercise of common stock warrant (in shares)	6
Share-based compensation		8,786					8,786
Other comprehensive income			597				597
Net (loss) income				4,522			4,522
Balance at Dec. 31, 2016	$ 34	308,815	648	(192,091)	$ (132)		$ 117,274
Balance (in shares) at Dec. 31, 2016	33,971				(28)		33,943
Stockholders' Deficit
Common stock issued under stock plans	$ 1	4,666					$ 4,667
Common stock issued under stock plans (in shares)	676
Share-based compensation		17,592					17,592
Other comprehensive income			(1,239)				(1,239)
Net (loss) income				(92)			(92)
Balance at Dec. 31, 2017	$ 35	$ 331,073	$ (591)	$ (192,183)	$ (132)		$ 138,202
Balance (in shares) at Dec. 31, 2017	34,647				(28)		34,619

CONSOLIDATED STATEMENTS OF CON7

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - TEMPORARY EQUITY - Convertible Preferred Stocks - 12 months ended Dec. 31, 2015 - USD ($) shares in Thousands, $ in Thousands	Series D convertible preferred stock	Total
Balance at Dec. 31, 2014		$ 157,379
Balance (in shares) at Dec. 31, 2014		21,642
Convertible Preferred Stock
Issuance of convertible preferred stock in connection with exercises of preferred stock warrants	$ 1,698
Issuance of convertible preferred stock in connection with exercises of preferred stock warrants (in shares)	94
Conversion of preferred stock into common stock		$ (159,077)
Conversion of preferred stock into common stock (in shares)		(21,736)
Balance at Dec. 31, 2015		$ 0
Balance (in shares) at Dec. 31, 2015		0

CONSOLIDATED STATEMENTS OF CON8

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - TEMPORARY EQUITY (PARENTHETICAL)	Dec. 31, 2015$ / shares
Series D convertible preferred stock
Convertible Preferred Stock
Share price (in dollars per share)	$ 18

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Activities
Net (loss) income	$ (92)	$ 4,522	$ (38,321)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization	5,482	4,722	4,267
Loss on disposal of fixed assets	6	40
Stock-based compensation	17,592	8,786	7,889
Loss on deconsolidation of DOSE			25,685
Loss on extinguishment of debt			186
Change in fair value of stock warrant liability		(43)	1,132
Unrealized foreign currency (gains) losses	(951)	368	192
Amortization of premium on short-term investments	20	210	51
Amortization of debt discount and deferred financing costs			15
Deferred rent	722	(31)	91
Change in operating assets and liabilities:
Accounts receivable, net	(2,181)	(6,791)	(2,163)
Inventory, net	(4,162)	(2,935)	(1,848)
Prepaid expenses and other current assets	494	(1,762)	(755)
Restricted cash	80
Accounts payable and accrued liabilities	9,741	5,096	1,518
Deferred tax asset, net	(235)
Other assets	(1,008)	127	(127)
Net cash provided by (used in) operating activities	25,508	12,309	(2,188)
Investing activities
Purchases of property and equipment	(6,311)	(6,278)	(877)
Purchase of iDOSE product line and related assets from DOSE Medical			(15,000)
Purchases of short-term investments	(94,307)	(75,192)	(69,751)
Proceeds from sale and maturities of short-term investments	88,891	55,354
Net cash used in investing activities	(11,727)	(26,116)	(85,628)
Financing activities
Proceeds from public offering, net of issuance costs			113,589
Proceeds from senior secured term and draw-to term loans			6,852
Payments of senior secured term and draw-to term loans			(7,000)
Proceeds from line of credit			1,750
Payments of line of credit			(3,600)
Payments of subordinated notes		(9,696)	(7,804)
Proceeds from exercise of stock options	3,699	6,059	1,734
Share purchases under Employee Stock Purchase Plan	968	1,945	1,161
Proceeds from exercise of stock warrants		50	428
Net cash provided by (used in) financing activities	4,667	(1,642)	107,110
Effect of exchange rate changes on cash and cash equivalents	(434)	371	(26)
Net increase (decrease) in cash and cash equivalents	18,014	(15,078)	19,268
Cash and cash equivalents at beginning of period	6,494	21,572	2,304
Cash and cash equivalents at end of period	24,508	6,494	21,572
Supplemental disclosures of cash flow information
Interest paid		285	834
Taxes paid, net of refunds	12	513	25
Supplemental schedule of noncash investing and financing activities
Purchase of intangible assets in exchange for future payments			243
Conversion of preferred stock into common stock			159,077
Reduction of liability upon vesting of stock options previously exercised for unvested stock	$ 4	$ 62	$ 86

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2017
Organization and Basis of Presentation
Organization and Basis of Presentation	Glaukos Corporation Notes to consolidated financial statements 1. Organization and business Liquidity Initial public offering Acquisition of the IOP Sensor System and certain assets from DOSE Medical On April 12, 2017, the Company entered into an IOP Sensor System Purchase Agreement (the Purchase Agreement), between the Company and DOSE, to purchase from DOSE its intraocular pressure (IOP) sensor system, including all patents, license rights and tangible assets, and to assume certain liabilities related thereto (collectively, the IOP Sensor System), for consideration consisting of an initial cash payment of $5.5 million, plus performance-based consideration of up to $9.5 million upon achievement of certain development, clinical and regulatory milestones. The Company completed the purchase of the IOP Sensor System concurrent with the execution of the Purchase Agreement. The transaction was accounted for as an asset acquisition. Of the $5.5 million initial cash payment, $5.3 million was immediately charged to in-process research and development expense as management determined there was no alternative future use related to the assets purchased. Of the remaining $0.2 million, the majority was capitalized to fixed assets and will be depreciated over the corresponding asset’s useful life, and a small portion was recorded as a prepaid asset and will be amortized to general and administrative expense as the underlying amounts are utilized. iDose product line and related assets from DOSE for a cash payment of $15.0 million and upon the acquisition, the Company derecognized DOSE as a consolidated entity in the financial statements. In addition to an asset purchase, the parties agreed to an amended and restated patent license agreement and an amended and restated transition services agreement that provides for limited support from the Company to DOSE for a period of up to three years, which period was extended through June 30, 2021 in connection with the Purchase Agreement (see Note 11). Thomas W. Burns, the Company’s President, Chief Executive and a member of its board of directors, and William J. Link, Ph.D., Chairman of the Company’s board of directors, currently serve on the board of directors of DOSE and certain members of the Company’s management and board of directors hold an equity interest in DOSE.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Basis of presentation Use of estimates Foreign currency translation Unrealized gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency, primarily gains and losses on intercompany loans, are included in the consolidated statements of operations as a component of other income, net. For the year ended December 31, 2017, the Company reported a net foreign currency transaction gain of $1.0 million and for the years ended December 31, 2016 and 2015, the Company reported net foreign currency transaction losses of $0.4 million and $0.2 million, respectively. Cash, cash equivalents and short-term investments Concentration of credit risk and significant customers Accounts receivable Inventory Long lived assets Intangible assets Fair value of financial instruments Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). Revenue recognition Shipping and handling costs Advertising costs Income taxes for federal tax purposes. However, the Company is still analyzing certain aspects of the Act and refining calculations, which could potentially affect the measurement of these balances or give rise to new deferred tax amounts. The provisional amount recorded related to the remeasurement of the deferred tax balance was $25.2 million, which was fully offset by a decrease in the valuation allowance. Research and development expenses Stock‑based compensation The Company recognizes compensation expense for all stock-based awards granted to employees and nonemployees, including members of its board of directors. The fair value of stock option awards is estimated at the grant date using the Black-Scholes option pricing model, and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period using the straight-line method. The determination of the fair value-based measurement of stock options on the date of grant using an option pricing model is affected by the determination of the fair value of the underlying stock as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s stock price volatility over the expected term of the grants, and actual and projected employee stock option exercise behaviors. In the future, as additional empirical evidence regarding these estimates becomes available, the Company may change or refine its approach of deriving them, and these changes could impact the fair value-based measurement of stock options granted in the future. Changes in the fair value-based measurement of stock awards could materially impact the Company’s operating results. The fair values of stock option awards made to nonemployees are remeasured at each reporting period using the Black-Scholes option pricing model. Compensation expense for these stock option awards is determined by applying the remeasured fair values to the shares that have vested during a period. The fair value of restricted stock unit (RSU) awards made to employees and nonemployees is equal to the closing market price of the Company’s common stock on the grant date. Comprehensive (loss) income Net (loss) income per share As of December 31, Numerator: Net (loss) income - basic $ (92) $ 4,522 $ (37,241) Denominator: Weighted average number of common shares outstanding - basic 34,381 32,928 17,474 Common stock equivalents from outstanding common stock options - 3,514 - Common stock equivalents for ESPP - 16 - Common stock equivalents from outstanding common stock warrants - 1 - Weighted average number of common shares outstanding - diluted 34,381 36,459 17,474 Basic net (loss) income per share $ $ 0.14 $ (2.13) Diluted net (loss) income per share $ $ 0.12 $ (2.13) As of December 31, Stock options outstanding 5,689 1,099 5,701 Employee stock purchase plan 28 — 89 Common stock warrants outstanding — — 6 5,717 1,099 5,796 Recently adopted accounting pronouncements In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09 , Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU 2016-09), which modifies certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards, and classification in the statement of cash flows. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments were effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods and the Company adopted ASU 2016-09 in its first quarter 2017. As a result of the prospective adoption of ASU 2016-09 on January 1, 2017, excess tax benefits of $13.1 million were recorded to the Company’s net operating loss carryover resulting in an increase in the Company’s deferred tax assets with an identical increase in the associated valuation allowance, and no prior periods have been adjusted. Recently issued accounting pronouncements not yet adopted In May 2014, the FASB issued guidance in ASU 2014-09 which was codified in Accounting Standards Codification (ASC) 606, Revenue Recognition – Revenue from Contracts with Customers (ASC 606). ASC 606 provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers, and is principles-based, such that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2015-14 deferred the effective date of ASC 606 to annual reporting periods beginning after December 15, 2017 (including interim periods within those periods) and while early adoption is permitted, the Company adopted ASC 606 on January 1, 2018. Companies are required to apply ASC 606 retrospectively; however, companies may use either a full retrospective or a modified retrospective approach when adopting the standard. The Company will be using the modified retrospective approach, and adoption of ASC 606 will not result in a cumulative catch-up adjustment to the opening balance sheet of retained earnings at the effective date. The Company has performed an analysis and does not believe adoption of the standard will have a material impact on its consolidated financial statements with the exception of enhanced disclosure requirements required by ASC 606. In the analysis, the Company has concluded it generally has one performance obligation, the transaction price is not impacted by any variable consideration or other factors noted in ASC 606, except for offering a right of return, and the Company’s performance obligations are generally satisfied when products are shipped. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The ASU requires management to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. The new standard must be adopted using the modified retrospective approach and will be effective for the Company starting in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements; however, the Company anticipates recognition of additional assets and corresponding liabilities on its consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (ASC 2016-18), which enhances and clarifies the guidance on the classification and presentation of restricted cash in the statement of cash flows. ASU 2016-18 was effective for the Company starting January 1, 2018. Currently, the Company's restricted cash balance is not significant and the Company does not expect the adoption of the guidance will have a material impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (ASU 2017-01), clarifying the definition of a business. The amendments are intended to help companies evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. When substantially all of the fair value of gross assets acquired is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. This introduces an initial required screening that, if met, eliminates the need for further assessment. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. To be a business without outputs, there will need to be an organized workforce. The ASU also narrows the definition of the term “outputs” to be consistent with how it is described in ASC 606, Revenue Recognition - Revenue from Contracts with Customers . The amendments are effective for annual periods beginning after December 15, 2017, including interim periods within those periods with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on its consolidated financial statements.

Balance Sheet Details

Balance Sheet Details	12 Months Ended
	Dec. 31, 2017
Balance Sheet Details
Balance Sheet Details	3. Short-term investments Short-term investments consisted of the following (in thousands): At December 31, 2017 Maturity Amortized cost Unrealized Unrealized Estimated (in years) or cost gains losses fair value U.S. government bonds less than 2 $ 1,799 $ — $ (17) $ 1,782 U.S. government agency bonds less than 2 2,698 — (17) 2,681 Bank certificates of deposit less than 1 10,300 1 (3) 10,298 Commercial paper less than 1 11,598 — (5) 11,593 Corporate notes less than 3 51,532 6 (121) 51,417 Asset-backed securities less than 3 16,796 — (61) 16,735 Total $ 94,723 $ 7 $ (224) $ 94,506 At December 31, 2016 Maturity Amortized cost Unrealized Unrealized Estimated (in years) or cost gains losses fair value U.S. government agency bonds 1-3 $ 9,535 $ 2 $ (22) $ 9,515 Bank certificates of deposit less than 2 11,101 13 (1) 11,113 Commercial paper less than 1 17,011 1 (2) 17,010 Corporate notes less than 3 45,178 7 (61) 45,124 Asset-backed securities less than 2 6,503 3 — 6,506 Total $ 89,328 $ 26 $ (86) $ 89,268 Accounts receivable, net Accounts receivable consisted of the following (in thousands): December 31, Accounts receivable $ 17,248 $ 14,800 Less allowance for doubtful accounts (592) (495) $ 16,656 $ 14,305 Inventory, net Inventory consisted of the following (in thousands): December 31, Finished goods $ 4,225 $ 2,014 Work in process 2,368 2,105 Raw material 4,629 2,725 $ 11,222 $ 6,844 Property and equipment, net Property and equipment consisted of the following (in thousands): December 31, Buildings $ 874 $ 874 Equipment 8,311 5,342 Furniture and fixtures 1,382 639 Leasehold improvements 4,568 3,474 Computer equipment and software 1,980 1,239 Construction in progress 1,134 1,320 18,249 12,888 Less accumulated depreciation and amortization (6,455) (5,295) $ 11,794 $ 7,593 Depreciation and amortization expense related to property and equipment was $2.1 million, $1.1 million and $0.8 million for the years ended December 31, 2017, 2016 and 2015, respectively. Accrued liabilities Accrued liabilities consisted of the following (in thousands): December 31, Accrued contract payments (see Note 10) $ 1,033 $ 823 Accrued sales commissions 506 1,641 Accrued clinical study payments 609 1,167 Accrued bonuses 9,106 6,122 Accrued vacation benefits 2,121 1,382 Accrued Employee Stock Purchase Plan liability 1,517 4 Other accrued liabilities 5,557 2,772 $ 20,449 $ 13,911

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Measurements
Fair Value Measurements	4. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2017 and 2016, and indicates the fair value hierarchy of the valuation techniques utilized by the Company to determine such fair value (in thousands). The Company did not have any financial liabilities measured at fair value on a recurring basis as of December 31, 2017 and December 31, 2016. At December 31, 2017 Significant Quoted prices in other Significant active markets for observable unobservable December 31, identical assets inputs inputs (Level 1) (Level 2) (Level 3) Assets Money market funds (i) $ 2,370 $ 2,370 $ — $ — U.S. government agency bonds (ii) 2,681 — 2,681 — U.S. Government bonds (ii) 1,782 — 1,782 — Bank certificates of deposit (ii) 10,298 — 10,298 — Commercial paper (ii) (iii) 14,593 — 14,593 — Corporate notes (ii) 51,417 — 51,417 — Asset-backed securities (ii) 16,735 — 16,735 — Total assets $ 99,876 $ 2,370 $ 97,506 $ — (i) Included in cash and cash equivalents with a maturity of three months or less from date of purchase on the consolidated balance sheets. (ii) Included in short-term investments on the consolidated balance sheets. (iii) One commercial paper investment totaling $3,000 (in thousands) is included in cash and cash equivalents on the condensed consolidated balance sheets, as the investment has a maturity of three months or less from the date of purchase on the condensed consolidated balance sheets. At December 31, 2016 Significant Quoted prices in other Significant active markets for observable unobservable December 31, identical assets inputs inputs (Level 1) (Level 2) (Level 3) Assets Money market funds (i) $ 80 $ 80 $ — $ — U.S. government agency bonds (ii) 9,515 — 9,515 — Bank certificates of deposit (ii) 11,113 — 11,113 — Commercial paper (ii) 17,010 — 17,010 — Corporate notes (ii) 45,124 — 45,124 — Asset-backed securities (ii) 6,506 — 6,506 — Total assets $ 89,348 $ 80 $ 89,268 $ — (i) Included in cash and cash equivalents with a maturity of three months or less from date of purchase on the consolidated balance sheets. (ii) Included in short-term investments on the consolidated balance sheets.

Long-Term Debt and Intangible A

Long-Term Debt and Intangible Assets	12 Months Ended
	Dec. 31, 2017
Long-Term Debt and Intangible Assets
Long-Term Debt and Intangible Assets	5. Notes payable in connection with GMP Vision Solutions In January 2007, the Company entered into an agreement (the Original GMP Agreement) with GMP Vision Solutions, Inc. (GMP) to acquire certain in‑process research and development in exchange for periodic royalty payments equal to a single‑digit percentage of revenues received for royalty‑bearing products and periodic royalty payments at a higher royalty rate applied to all amounts received in connection with the grant of licenses or sub-licenses of the related intellectual property. For each of the years ended December 31, 2017, 2016 and 2015, the Company recorded amortization expense of $3.5 million related to this intangible asset in cost of sales . Bank loan facility Intangible assets December 31, December 31, GMP royalty buyout $ 17,500 $ 17,500 Non-compete agreements 524 243 18,024 17,743 Accumulated amortization (14,877) (11,176) Total $ 3,147 $ 6,567 Weighted average amortization period (in months) 60 60 Estimated amortization expense will be $3.1 million in 2018 after which the above mentioned intangible assets will be fully amortized.

Convertible Preferred Stock and

Convertible Preferred Stock and Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Convertible Preferred Stock and Stockholders' Equity
Convertible Preferred Stock and Stockholders' Equity	6. Convertible preferred stock Preferred stock Common stock

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2017
Stock-Based Compensation.
Stock-Based Compensation	7. The Company has four stock‑based compensation plans (collectively, the Stock Plans)—the 2001 Stock Option Plan (the 2001 Stock Plan), the 2011 Stock Plan (the 2011 Stock Plan), the 2015 Omnibus Incentive Compensation Plan (the 2015 Stock Plan) and the 2015 Employee Stock Purchase Plan (the ESPP). The 2015 Stock Plan permits grants of restricted stock units (RSUs). The Company has historically granted stock options, but the Company began to award RSU grants to certain employees during the fiscal year ended 2017. RSU awards vest 25% on each of the first, second, third and fourth anniversaries of the grant date. and $4,000, respectively. Stock options Number of Weighted- shares Weighted- average Aggregate underlying average remaining intrinsic options exercise price contractual value (in (in thousands) per share life (in years) thousands) Outstanding at December 31, 2014 5,657 $ 3.93 6.3 $ 16,131 Granted 1,139 18.07 Exercised (1,022) 1.70 9,174 Canceled/forfeited/expired (73) 6.56 Outstanding at December 31, 2015 5,701 $ 7.10 6.7 $ 102,390 Granted 1,979 21.24 Exercised (1,660) 3.65 42,458 Canceled/forfeited/expired (109) 20.00 Outstanding at December 31, 2016 5,911 $ 12.59 7.3 $ 129,591 Granted 1,877 43.85 Exercised (639) 5.76 22,105 Canceled/forfeited/expired (123) 23.79 Outstanding at December 31, 2017 7,026 $ 21.36 7.3 $ 69,555 Vested and expected to vest at December 31, 2017 6,893 $ 21.13 7.2 $ 69,080 Exercisable at December 31, 2017 3,687 $ 10.58 5.9 $ 57,987 Intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that had exercise prices that were lower than the fair value per share of the common stock on the date of exercise. Restricted Stock Units Weighted- Number of average shares grant date (in thousands) fair value Unvested at December 31, 2016 — $ — Granted 173 39.10 Vested — — Canceled/forfeited — — Unvested at December 31, 2017 173 39.10 Valuation and expense recognition of stock-based awards The risk‑free interest rate is equal to the U.S. Treasury Note interest rate for the comparable term for the expected option life as of the valuation date. If the expected option life is between the U.S. Treasury Note rates of two published terms, then the risk‑free interest rate is based on the straight‑line interpolation between the U.S. Treasury Note rates of the two published terms as of the valuation date. The expected dividend yield is based on the Company’s history and expectation of dividend payouts. The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. The Company only recently began to have publicly traded equity and has a limited operating history and a lack of Company‑specific historical and implied volatility data, and therefore has estimated its stock price volatility based upon an index of the historical volatilities of a group of comparable publicly‑traded medical device peer companies. The historical volatility data was computed using the historical daily closing prices for the selected peer companies’ shares during the equivalent period of the calculated expected term of the Company’s stock options. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term, and therefore it uses the simplified method for estimating the expected term of stock option grants. Under this approach, the weighted‑average expected term is presumed to be the average of the vesting term and the contractual term of the option. Historically, and until the June 30, 2015 completion of the Company’s IPO, the fair value of the shares of common stock underlying the stock options has been the responsibility of and determined by the Company’s Board of Directors. Because there had been no public market for the Company’s common stock, the Board of Directors determined the fair value of common stock at the time of grant of the option by considering a number of objective and subjective factors including independent third‑party valuations of the Company’s common stock, sales prices of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock and general and industry specific economic outlook, among other factors. Subsequent to the date of the Company’s IPO in June 2015, the Company has used the daily market prices in the determination of the fair value of its common stock. Stock‑based awards to employees The weighted‑average assumptions used to estimate the fair value of stock options granted to employees were as follows: Year ended December 31, Risk-free interest rate 2.13 % 1.59 % 1.77 % Expected dividend yield 0.0 % 0.0 % 0.0 % Expected volatility 46.5 % 52.9 % 56.0 % Expected term (in years) 6.04 6.04 6.07 The Company reduces employee share‑based compensation expense for estimated forfeitures. Forfeitures are estimated at the time of grant based on historical experience, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock‑based awards to nonemployees Year ended December 31, Cost of sales $ 597 $ 233 $ 251 Selling, general & administrative 13,006 6,475 5,773 Research and development 3,989 2,078 1,865 Total $ 17,592 $ 8,786 $ 7,889 Common stock reserved for future issuance As of December 31, Stock options issued and outstanding—2001 Plan 811 Stock options issued and outstanding—2011 Plan 2,001 Stock options issued and outstanding—2015 Plan 4,388 Employee stock purchase plan 838 Authorized for future stock awards or option grants 3,443 11,481

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Taxes
Income Taxes	8. Year ended December 31, United States $ 12,543 $ 12,214 $ (36,750) Foreign (12,542) (7,649) (1,538) Total $ 1 $ 4,565 $ (38,288) December 31, Current: Federal $ 235 $ (28) $ — State 93 71 33 Foreign — — — 328 43 33 Deferred: Federal (235) — — State — — — Foreign — — — (235) — — Provision for income taxes $ 93 $ 43 $ 33 Year ended December 31, (amounts in thousands) Statutory rate of tax expense $ - $ 1,552 $ (13,018) State income taxes, net of federal benefit (17) 530 (1,347) Permanent and other items (5,199) 789 1,307 Deconsolidation of DOSE - - 4,558 Nondeductible offering costs - 7 - Research credits (2,215) (1,945) (1,745) Uncertain tax positions 1,108 940 865 Change in tax rate 1,013 1,337 68 Tax Cuts and Jobs Act 25,216 - - Valuation allowance (19,813) (3,167) 9,345 Provision for income taxes $ 93 $ 43 $ 33 December 31, Deferred tax assets: Net operating loss carryforwards $ 37,571 $ 41,144 Tax credits 6,713 4,913 Depreciation and amortization 10,765 16,748 Stock-based compensation 7,184 5,310 Reserves and accruals 3,739 3,920 Other, net — 233 Total deferred tax assets 65,972 72,268 Deferred tax liabilities: Other, net $ (42) $ — Valuation allowance (65,695) (72,268) Net deferred tax assets $ 235 $ — December 31, Balance at beginning of the year $ 5,947 $ 4,848 $ 4,066 Reductions for tax positions—prior years — (49) (284) Additions for tax positions—current year 1,280 1,148 1,066 Balance at end of the year $ 7,227 $ 5,947 $ 4,848 The Tax Cuts and Jobs Act

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2017
Employee Benefits
Employee Benefits	9. Defined contribution plan Deferred compensation plan Effective April 1, 2017, the Company established a deferred compensation plan (the Deferred Compensation Plan) for eligible senior level employees. The plan is designed to permit eligible employees to make elective deferrals of compensation to which he or she will become entitled in the future. The Company also established a rabbi trust that serves as an investment to shadow the Deferred Compensation Plan liability. The investments of the rabbi trust consist of company-owned life insurance policies (COLIs). The fair value of the Deferred Compensation Plan liability, included in other liabilities on the consolidated balance sheets, was approximately $0.6 million as of December 31, 2017 and the cash surrender value of the COLIs, included in deposits and other assets on the consolidated balance sheets, which reflects the underlying assets at fair value, was approximately $0.7 million as of December 31, 2017.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies
Commitments and Contingencies	10. Operating leases The Company leases two adjacent facilities located in San Clemente, California, both of which are subject to leases that expire on December 31, 2021. The agreements each contain an option to extend the leases for up to two additional three-year periods at market rates. The total square footage of both facilities equals approximately 77,000. The lease landlord agreed to provide the Company with a tenant improvement allowance after January 1, 2017 in the amount of the cost of any leasehold improvements, not to exceed approximately $264,000 upon the Company providing the necessary documentation evidencing the costs of the allowable leasehold improvements. The Company’s remaining U.S.-based and foreign subsidiaries’ leased office space totals less than 14,000 square feet. 2018 $ 1,513 2019 1,340 2020 1,278 2021 1,251 2022 — Thereafter — $ 5,382 Purchase commitment Regents of the University of California iStent products, with a required minimum annual payment of $0.5 million. This ongoing product payment terminates on the date that the last of the Patent Rights expires, which is currently expected to be in 2022. For the years ended December 31, 2017, 2016 and 2015, the Company recorded approximately $3.9 million, $2.8 million and $1.8 million in cost of sales, respectively, in connection with the product payment obligation.

Variable Interest Entity

Variable Interest Entity	12 Months Ended
	Dec. 31, 2017
Variable Interest Entity
Variable Interest Entity	11. iDose product line, in exchange for payment of $15.0 million in cash and the elimination of the $10.9 million intercompany receivable owed by DOSE to the Company as of the closing date. The Company reconsidered its relationship with DOSE as a result of the transaction and determined it was no longer considered to be the primary beneficiary with the power to direct operations and the right to receive benefits/absorb losses of DOSE; therefore, upon the close of the transaction, the Company derecognized DOSE and no longer considered it a consolidated entity in its financial statements. Accordingly, in the three months ended June 30, 2015, the Company recorded a charge to other expense in the amount of $25.7 million to reflect the deconsolidation of DOSE’ non‑glaucoma related assets and noncontrolling interest. Year ended December 31, Selling, general & administrative $ — $ — $ 105 Research and development — — 890 Interest expense — — 85 Net loss of DOSE $ — $ — $ 1,080 Year ended December 31, Cash used in operating activities $ — $ — $ (1,134) Cash used in investing activities — — (33) Cash provided by financing activities — — 1,158 (Decrease) increase in cash and cash equivalents of DOSE $ — $ — $ (9)

Business Segment Information

Business Segment Information	12 Months Ended
	Dec. 31, 2017
Business Segment Information
Business Segment Information	12. Year ended December 31, Geographic net sales information (in thousands) United States $ 140,902 $ 104,995 $ 67,698 International 18,352 9,402 4,002 Total net sales $ 159,254 $ 114,397 $ 71,700 Property and equipment, net Depreciation and amortization Capital expenditures As of December 31, Year ended December 31, Year ended December 31, United States $ 11,677 $ 7,463 $ 2,012 $ 5,406 $ 4,654 $ 4,180 $ 6,051 $ 6,493 $ 972 International 117 130 142 76 68 87 221 56 62 Total $ 11,794 $ 7,593 $ 2,154 $ 5,482 $ 4,722 $ 4,267 $ 6,272 $ 6,549 $ 1,034

Selected Quarterly Financial In

Selected Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2017
Selected Quarterly Financial Information (Unaudited)
Selected Quarterly Financial Information (Unaudited)	13. Three months ended March 31, June 30, September 30, December 31, (in thousands, except per share amounts) Net sales $ 35,907 $ 41,285 $ 40,412 $ 41,650 Cost of sales 5,180 5,522 5,718 4,630 Gross profit 30,727 35,763 34,694 37,020 Operating expenses: Selling, general and administrative 21,481 24,675 24,141 25,963 In-process research and development — 5,320 — — Research and development 8,942 9,633 9,805 10,525 Total operating expenses 30,423 39,628 33,946 36,488 Income (loss) from operations 304 (3,865) 748 532 Total other income (expense), net 629 586 630 437 Provision for income taxes 55 22 53 (37) Net income (loss) $ 878 $ (3,301) $ 1,325 $ 1,006 Net income (loss) per share (1) : Basic $ 0.03 $ (0.10) $ 0.04 $ 0.03 Diluted $ 0.02 $ (0.10) $ 0.04 $ 0.03 Three months ended March 31, June 30, September 30, December 31, (in thousands, except per share amounts) Net sales $ 23,092 $ 28,556 $ 29,577 $ 33,172 Cost of sales 3,121 4,359 3,886 4,811 Gross profit 19,971 24,197 25,691 28,361 Operating expenses: Selling, general and administrative 12,288 15,120 16,854 20,494 Research and development 7,062 6,955 7,807 7,399 Total operating expenses 19,350 22,075 24,661 27,893 Income from operations 621 2,122 1,030 468 Total other income (expense), net 276 210 269 (431) Provision for income taxes — — 140 (97) Net income $ 897 $ 2,332 $ 1,159 $ 134 Net income per share (1) : Basic $ 0.03 $ 0.07 $ 0.03 $ Diluted $ 0.03 $ 0.06 $ 0.03 $ (1) Net income or loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per-share amounts will not necessarily equal the annual per share amount.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events
Subsequent Events	14. Subsequent events None.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Summary of Significant Accounting Policies
Basis of Presentation	Basis of presentation
Use of estimates	Use of estimates
Foreign currency translation	Foreign currency translation Unrealized gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency, primarily gains and losses on intercompany loans, are included in the consolidated statements of operations as a component of other income, net. For the year ended December 31, 2017, the Company reported a net foreign currency transaction gain of $1.0 million and for the years ended December 31, 2016 and 2015, the Company reported net foreign currency transaction losses of $0.4 million and $0.2 million, respectively.
Cash, cash equivalents and short-term investments	Cash, cash equivalents and short-term investments
Concentration of Credit Risk and Significant Customers	Concentration of credit risk and significant customers
Accounts Receivable	Accounts receivable
Inventory	Inventory
Long Lived Assets	Long lived assets
Intangible Assets	Intangible assets
Fair value of financial instruments	Fair value of financial instruments Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
Revenue recognition	Revenue recognition
Shipping and Handling Costs	Shipping and handling costs
Advertising Costs	Advertising costs
Income Taxes	Income taxes for federal tax purposes. However, the Company is still analyzing certain aspects of the Act and refining calculations, which could potentially affect the measurement of these balances or give rise to new deferred tax amounts. The provisional amount recorded related to the remeasurement of the deferred tax balance was $25.2 million, which was fully offset by a decrease in the valuation allowance.
Research and development expenses	Research and development expenses
Stock-based compensation	Stock‑based compensation The Company recognizes compensation expense for all stock-based awards granted to employees and nonemployees, including members of its board of directors. The fair value of stock option awards is estimated at the grant date using the Black-Scholes option pricing model, and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period using the straight-line method. The determination of the fair value-based measurement of stock options on the date of grant using an option pricing model is affected by the determination of the fair value of the underlying stock as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s stock price volatility over the expected term of the grants, and actual and projected employee stock option exercise behaviors. In the future, as additional empirical evidence regarding these estimates becomes available, the Company may change or refine its approach of deriving them, and these changes could impact the fair value-based measurement of stock options granted in the future. Changes in the fair value-based measurement of stock awards could materially impact the Company’s operating results. The fair values of stock option awards made to nonemployees are remeasured at each reporting period using the Black-Scholes option pricing model. Compensation expense for these stock option awards is determined by applying the remeasured fair values to the shares that have vested during a period. The fair value of restricted stock unit (RSU) awards made to employees and nonemployees is equal to the closing market price of the Company’s common stock on the grant date.
Comprehensive (Loss) Income	Comprehensive (loss) income
Net (loss) income per share	Net (loss) income per share As of December 31, Numerator: Net (loss) income - basic $ (92) $ 4,522 $ (37,241) Denominator: Weighted average number of common shares outstanding - basic 34,381 32,928 17,474 Common stock equivalents from outstanding common stock options - 3,514 - Common stock equivalents for ESPP - 16 - Common stock equivalents from outstanding common stock warrants - 1 - Weighted average number of common shares outstanding - diluted 34,381 36,459 17,474 Basic net (loss) income per share $ $ 0.14 $ (2.13) Diluted net (loss) income per share $ $ 0.12 $ (2.13) As of December 31, Stock options outstanding 5,689 1,099 5,701 Employee stock purchase plan 28 — 89 Common stock warrants outstanding — — 6 5,717 1,099 5,796
Recent accounting pronouncements	Recently adopted accounting pronouncements In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09 , Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU 2016-09), which modifies certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards, and classification in the statement of cash flows. The amendments are intended to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments were effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods and the Company adopted ASU 2016-09 in its first quarter 2017. As a result of the prospective adoption of ASU 2016-09 on January 1, 2017, excess tax benefits of $13.1 million were recorded to the Company’s net operating loss carryover resulting in an increase in the Company’s deferred tax assets with an identical increase in the associated valuation allowance, and no prior periods have been adjusted. Recently issued accounting pronouncements not yet adopted In May 2014, the FASB issued guidance in ASU 2014-09 which was codified in Accounting Standards Codification (ASC) 606, Revenue Recognition – Revenue from Contracts with Customers (ASC 606). ASC 606 provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers, and is principles-based, such that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2015-14 deferred the effective date of ASC 606 to annual reporting periods beginning after December 15, 2017 (including interim periods within those periods) and while early adoption is permitted, the Company adopted ASC 606 on January 1, 2018. Companies are required to apply ASC 606 retrospectively; however, companies may use either a full retrospective or a modified retrospective approach when adopting the standard. The Company will be using the modified retrospective approach, and adoption of ASC 606 will not result in a cumulative catch-up adjustment to the opening balance sheet of retained earnings at the effective date. The Company has performed an analysis and does not believe adoption of the standard will have a material impact on its consolidated financial statements with the exception of enhanced disclosure requirements required by ASC 606. In the analysis, the Company has concluded it generally has one performance obligation, the transaction price is not impacted by any variable consideration or other factors noted in ASC 606, except for offering a right of return, and the Company’s performance obligations are generally satisfied when products are shipped. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The ASU requires management to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. The new standard must be adopted using the modified retrospective approach and will be effective for the Company starting in the first quarter of 2019. Early adoption is permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements; however, the Company anticipates recognition of additional assets and corresponding liabilities on its consolidated financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (ASC 2016-18), which enhances and clarifies the guidance on the classification and presentation of restricted cash in the statement of cash flows. ASU 2016-18 was effective for the Company starting January 1, 2018. Currently, the Company's restricted cash balance is not significant and the Company does not expect the adoption of the guidance will have a material impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (ASU 2017-01), clarifying the definition of a business. The amendments are intended to help companies evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. When substantially all of the fair value of gross assets acquired is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. This introduces an initial required screening that, if met, eliminates the need for further assessment. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. To be a business without outputs, there will need to be an organized workforce. The ASU also narrows the definition of the term “outputs” to be consistent with how it is described in ASC 606, Revenue Recognition - Revenue from Contracts with Customers . The amendments are effective for annual periods beginning after December 15, 2017, including interim periods within those periods with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on its consolidated financial statements.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Summary of Significant Accounting Policies
Schedule of the Company's net income per share	The Company’s computation of net (loss) income per share is as follows (in thousands, except per share amounts): As of December 31, Numerator: Net (loss) income - basic $ (92) $ 4,522 $ (37,241) Denominator: Weighted average number of common shares outstanding - basic 34,381 32,928 17,474 Common stock equivalents from outstanding common stock options - 3,514 - Common stock equivalents for ESPP - 16 - Common stock equivalents from outstanding common stock warrants - 1 - Weighted average number of common shares outstanding - diluted 34,381 36,459 17,474 Basic net (loss) income per share $ $ 0.14 $ (2.13) Diluted net (loss) income per share $ $ 0.12 $ (2.13)
Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders	Potentially dilutive securities not included in the calculation of diluted net (loss) income per share because to do so would be anti‑dilutive were as follows (in common stock equivalent shares, in thousands): As of December 31, Stock options outstanding 5,689 1,099 5,701 Employee stock purchase plan 28 — 89 Common stock warrants outstanding — — 6 5,717 1,099 5,796

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	12 Months Ended
	Dec. 31, 2017
Balance Sheet Details
Schedule of short-term investments	3. Short-term investments Short-term investments consisted of the following (in thousands): At December 31, 2017 Maturity Amortized cost Unrealized Unrealized Estimated (in years) or cost gains losses fair value U.S. government bonds less than 2 $ 1,799 $ — $ (17) $ 1,782 U.S. government agency bonds less than 2 2,698 — (17) 2,681 Bank certificates of deposit less than 1 10,300 1 (3) 10,298 Commercial paper less than 1 11,598 — (5) 11,593 Corporate notes less than 3 51,532 6 (121) 51,417 Asset-backed securities less than 3 16,796 — (61) 16,735 Total $ 94,723 $ 7 $ (224) $ 94,506 At December 31, 2016 Maturity Amortized cost Unrealized Unrealized Estimated (in years) or cost gains losses fair value U.S. government agency bonds 1-3 $ 9,535 $ 2 $ (22) $ 9,515 Bank certificates of deposit less than 2 11,101 13 (1) 11,113 Commercial paper less than 1 17,011 1 (2) 17,010 Corporate notes less than 3 45,178 7 (61) 45,124 Asset-backed securities less than 2 6,503 3 — 6,506 Total $ 89,328 $ 26 $ (86) $ 89,268
Schedule of accounts receivable, net	Accounts receivable consisted of the following (in thousands): December 31, Accounts receivable $ 17,248 $ 14,800 Less allowance for doubtful accounts (592) (495) $ 16,656 $ 14,305
Schedule of inventory	Inventory consisted of the following (in thousands): December 31, Finished goods $ 4,225 $ 2,014 Work in process 2,368 2,105 Raw material 4,629 2,725 $ 11,222 $ 6,844
Schedule of property and equipment, net	Property and equipment consisted of the following (in thousands): December 31, Buildings $ 874 $ 874 Equipment 8,311 5,342 Furniture and fixtures 1,382 639 Leasehold improvements 4,568 3,474 Computer equipment and software 1,980 1,239 Construction in progress 1,134 1,320 18,249 12,888 Less accumulated depreciation and amortization (6,455) (5,295) $ 11,794 $ 7,593
Schedule of accrued liabilities	Accrued liabilities consisted of the following (in thousands): December 31, Accrued contract payments (see Note 10) $ 1,033 $ 823 Accrued sales commissions 506 1,641 Accrued clinical study payments 609 1,167 Accrued bonuses 9,106 6,122 Accrued vacation benefits 2,121 1,382 Accrued Employee Stock Purchase Plan liability 1,517 4 Other accrued liabilities 5,557 2,772 $ 20,449 $ 13,911

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Measurements
Schedule of the Company's financial assets and financial liabilities measured at fair value on a recurring basis	The Company did not have any financial liabilities measured at fair value on a recurring basis as of December 31, 2017 and December 31, 2016. At December 31, 2017 Significant Quoted prices in other Significant active markets for observable unobservable December 31, identical assets inputs inputs (Level 1) (Level 2) (Level 3) Assets Money market funds (i) $ 2,370 $ 2,370 $ — $ — U.S. government agency bonds (ii) 2,681 — 2,681 — U.S. Government bonds (ii) 1,782 — 1,782 — Bank certificates of deposit (ii) 10,298 — 10,298 — Commercial paper (ii) (iii) 14,593 — 14,593 — Corporate notes (ii) 51,417 — 51,417 — Asset-backed securities (ii) 16,735 — 16,735 — Total assets $ 99,876 $ 2,370 $ 97,506 $ — (i) Included in cash and cash equivalents with a maturity of three months or less from date of purchase on the consolidated balance sheets. (ii) Included in short-term investments on the consolidated balance sheets. (iii) One commercial paper investment totaling $3,000 (in thousands) is included in cash and cash equivalents on the condensed consolidated balance sheets, as the investment has a maturity of three months or less from the date of purchase on the condensed consolidated balance sheets. At December 31, 2016 Significant Quoted prices in other Significant active markets for observable unobservable December 31, identical assets inputs inputs (Level 1) (Level 2) (Level 3) Assets Money market funds (i) $ 80 $ 80 $ — $ — U.S. government agency bonds (ii) 9,515 — 9,515 — Bank certificates of deposit (ii) 11,113 — 11,113 — Commercial paper (ii) 17,010 — 17,010 — Corporate notes (ii) 45,124 — 45,124 — Asset-backed securities (ii) 6,506 — 6,506 — Total assets $ 89,348 $ 80 $ 89,268 $ — (i) Included in cash and cash equivalents with a maturity of three months or less from date of purchase on the consolidated balance sheets. (ii) Included in short-term investments on the consolidated balance sheets.

Long-Term Debt and Intangible28

Long-Term Debt and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Long-Term Debt and Intangible Assets
Schedule reflecting the composition of intangible assets, net	December 31, December 31, GMP royalty buyout $ 17,500 $ 17,500 Non-compete agreements 524 243 18,024 17,743 Accumulated amortization (14,877) (11,176) Total $ 3,147 $ 6,567 Weighted average amortization period (in months) 60 60

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Stock-Based Compensation.
Schedule summarizing stock option activity under the 2001 Stock Plan, 2011 Stock Plan and 2015 Stock Plan	Stock options Number of Weighted- shares Weighted- average Aggregate underlying average remaining intrinsic options exercise price contractual value (in (in thousands) per share life (in years) thousands) Outstanding at December 31, 2014 5,657 $ 3.93 6.3 $ 16,131 Granted 1,139 18.07 Exercised (1,022) 1.70 9,174 Canceled/forfeited/expired (73) 6.56 Outstanding at December 31, 2015 5,701 $ 7.10 6.7 $ 102,390 Granted 1,979 21.24 Exercised (1,660) 3.65 42,458 Canceled/forfeited/expired (109) 20.00 Outstanding at December 31, 2016 5,911 $ 12.59 7.3 $ 129,591 Granted 1,877 43.85 Exercised (639) 5.76 22,105 Canceled/forfeited/expired (123) 23.79 Outstanding at December 31, 2017 7,026 $ 21.36 7.3 $ 69,555 Vested and expected to vest at December 31, 2017 6,893 $ 21.13 7.2 $ 69,080 Exercisable at December 31, 2017 3,687 $ 10.58 5.9 $ 57,987
Schedule summarizing restricted stock unit activity	Restricted Stock Units Weighted- Number of average shares grant date (in thousands) fair value Unvested at December 31, 2016 — $ — Granted 173 39.10 Vested — — Canceled/forfeited — — Unvested at December 31, 2017 173 39.10
Schedule of the weighted-average assumptions used to estimate the fair value of options granted to employees	Year ended December 31, Risk-free interest rate 2.13 % 1.59 % 1.77 % Expected dividend yield 0.0 % 0.0 % 0.0 % Expected volatility 46.5 % 52.9 % 56.0 % Expected term (in years) 6.04 6.04 6.07
Schedule summarizing the allocation of stock-based compensation	The following table summarizes the allocation of stock‑based compensation related to stock options and restricted stock units in the accompanying consolidated statements of operations (in thousands): Year ended December 31, Cost of sales $ 597 $ 233 $ 251 Selling, general & administrative 13,006 6,475 5,773 Research and development 3,989 2,078 1,865 Total $ 17,592 $ 8,786 $ 7,889
Schedule of Common stock reserved for issuance	As of December 31, Stock options issued and outstanding—2001 Plan 811 Stock options issued and outstanding—2011 Plan 2,001 Stock options issued and outstanding—2015 Plan 4,388 Employee stock purchase plan 838 Authorized for future stock awards or option grants 3,443 11,481

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Taxes
Schedule of United States and foreign loss before income taxes	Year ended December 31, United States $ 12,543 $ 12,214 $ (36,750) Foreign (12,542) (7,649) (1,538) Total $ 1 $ 4,565 $ (38,288)
Schedule of the provision for income taxes	December 31, Current: Federal $ 235 $ (28) $ — State 93 71 33 Foreign — — — 328 43 33 Deferred: Federal (235) — — State — — — Foreign — — — (235) — — Provision for income taxes $ 93 $ 43 $ 33
Schedule of reconciliations of the U.S. federal statutory tax rate to the combined effective tax rate	Year ended December 31, (amounts in thousands) Statutory rate of tax expense $ - $ 1,552 $ (13,018) State income taxes, net of federal benefit (17) 530 (1,347) Permanent and other items (5,199) 789 1,307 Deconsolidation of DOSE - - 4,558 Nondeductible offering costs - 7 - Research credits (2,215) (1,945) (1,745) Uncertain tax positions 1,108 940 865 Change in tax rate 1,013 1,337 68 Tax Cuts and Jobs Act 25,216 - - Valuation allowance (19,813) (3,167) 9,345 Provision for income taxes $ 93 $ 43 $ 33
Schedule of significant components of the Company's deferred tax assets	Significant components of the Company’s net deferred tax assets at December 31, 2017 and 2016 are as follows (in thousands): December 31, Deferred tax assets: Net operating loss carryforwards $ 37,571 $ 41,144 Tax credits 6,713 4,913 Depreciation and amortization 10,765 16,748 Stock-based compensation 7,184 5,310 Reserves and accruals 3,739 3,920 Other, net — 233 Total deferred tax assets 65,972 72,268 Deferred tax liabilities: Other, net $ (42) $ — Valuation allowance (65,695) (72,268) Net deferred tax assets $ 235 $ —
Schedule of reconciliation of the beginning and ending amount of gross unrecognized tax benefits, excluding interest and penalties	December 31, Balance at beginning of the year $ 5,947 $ 4,848 $ 4,066 Reductions for tax positions—prior years — (49) (284) Additions for tax positions—current year 1,280 1,148 1,066 Balance at end of the year $ 7,227 $ 5,947 $ 4,848

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies
Schedule of future minimum lease payments under noncancelable operating leases	2018 $ 1,513 2019 1,340 2020 1,278 2021 1,251 2022 — Thereafter — $ 5,382

Variable Interest Entity (Table

Variable Interest Entity (Tables)	12 Months Ended
	Dec. 31, 2017
Variable Interest Entity
Schedule of DOSE's financial information included in the accompanying financial statements:	Consolidation of DOSE’s results of operations included the following (in thousands): Year ended December 31, Selling, general & administrative $ — $ — $ 105 Research and development — — 890 Interest expense — — 85 Net loss of DOSE $ — $ — $ 1,080 Year ended December 31, Cash used in operating activities $ — $ — $ (1,134) Cash used in investing activities — — (33) Cash provided by financing activities — — 1,158 (Decrease) increase in cash and cash equivalents of DOSE $ — $ — $ (9)

Business Segment Information (T

Business Segment Information (Tables)	12 Months Ended
	Dec. 31, 2017
Business Segment Information
Schedule of Geographic Net Sales Information	Year ended December 31, Geographic net sales information (in thousands) United States $ 140,902 $ 104,995 $ 67,698 International 18,352 9,402 4,002 Total net sales $ 159,254 $ 114,397 $ 71,700
Schedule of Property and Equipment, net, Depreciation and Amortization, and Capital Expenditures by Geographic Area	Property and equipment, net Depreciation and amortization Capital expenditures As of December 31, Year ended December 31, Year ended December 31, United States $ 11,677 $ 7,463 $ 2,012 $ 5,406 $ 4,654 $ 4,180 $ 6,051 $ 6,493 $ 972 International 117 130 142 76 68 87 221 56 62 Total $ 11,794 $ 7,593 $ 2,154 $ 5,482 $ 4,722 $ 4,267 $ 6,272 $ 6,549 $ 1,034

Selected Quarterly Financial 34

Selected Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Selected Quarterly Financial Information (Unaudited)
Schedule of Quarterly Financial information	Three months ended March 31, June 30, September 30, December 31, (in thousands, except per share amounts) Net sales $ 35,907 $ 41,285 $ 40,412 $ 41,650 Cost of sales 5,180 5,522 5,718 4,630 Gross profit 30,727 35,763 34,694 37,020 Operating expenses: Selling, general and administrative 21,481 24,675 24,141 25,963 In-process research and development — 5,320 — — Research and development 8,942 9,633 9,805 10,525 Total operating expenses 30,423 39,628 33,946 36,488 Income (loss) from operations 304 (3,865) 748 532 Total other income (expense), net 629 586 630 437 Provision for income taxes 55 22 53 (37) Net income (loss) $ 878 $ (3,301) $ 1,325 $ 1,006 Net income (loss) per share (1) : Basic $ 0.03 $ (0.10) $ 0.04 $ 0.03 Diluted $ 0.02 $ (0.10) $ 0.04 $ 0.03 Three months ended March 31, June 30, September 30, December 31, (in thousands, except per share amounts) Net sales $ 23,092 $ 28,556 $ 29,577 $ 33,172 Cost of sales 3,121 4,359 3,886 4,811 Gross profit 19,971 24,197 25,691 28,361 Operating expenses: Selling, general and administrative 12,288 15,120 16,854 20,494 Research and development 7,062 6,955 7,807 7,399 Total operating expenses 19,350 22,075 24,661 27,893 Income from operations 621 2,122 1,030 468 Total other income (expense), net 276 210 269 (431) Provision for income taxes — — 140 (97) Net income $ 897 $ 2,332 $ 1,159 $ 134 Net income per share (1) : Basic $ 0.03 $ 0.07 $ 0.03 $ Diluted $ 0.03 $ 0.06 $ 0.03 $ (1) Net income or loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per-share amounts will not necessarily equal the annual per share amount.

Organization and Basis of Pre35

Organization and Basis of Presentation - Liquidity (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Organization and Basis of Presentation
Net (loss) income	$ 1,006	$ 1,325	$ (3,301)	$ 878	$ 134	$ 1,159	$ 2,332	$ 897	$ (92)	$ 4,522	$ (37,241)
Cash used in operating activities									25,508	12,309	$ (2,188)
Accumulated deficit	(192,183)				$ (192,091)				(192,183)	$ (192,091)
Cash, cash equivalents, and short-term investments	119,000								119,000
Net working capital	$ 123,000								$ 123,000

Organization and Basis of Pre36

Organization and Basis of Presentation - IPO (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2015	Jun. 29, 2015
Organization and Basis of Presentation
Proceeds from public offering, net of issuance costs			$ 113,589
Common shares issued upon the conversion of convertible preferred stock (in shares)		21,736,367
Shares outstanding	0
Warrants to Purchase Shares of Series D Convertible Preferred Stock
Organization and Basis of Presentation
Warrants outstanding (in shares)	0
Convertible Preferred Stock
Organization and Basis of Presentation
Common shares issued upon the conversion of convertible preferred stock (in shares)	21,700,000
Shares outstanding	0	0	0	21,736,367
Common Stock
Organization and Basis of Presentation
Shares issued			6,900,000
Common shares issued upon the conversion of convertible preferred stock (in shares)			21,736,000
Common Stock | IPO
Organization and Basis of Presentation
Shares issued	6,900,000
Share price (in dollars per share)	$ 18
Proceeds from public offering, net of issuance costs	$ 113,600
Underwriting commissions	8,700
Stock issuance costs	$ 1,900
Omnibus Incentive Compensation Plan 2015
Organization and Basis of Presentation
Shares reserved for future issuance	4,500,000
Employee Stock Purchase Plan 2015
Organization and Basis of Presentation
Shares reserved for future issuance	450,000

Organization and Basis of Pre37

Organization and Basis of Presentation - IOP and DOSE Medical (Details) - USD ($) $ in Thousands	Apr. 12, 2017	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2015
Acquisition of IOP Sensor System
Cash payments for the acquisition of certain assets of related party				$ 15,000
In-process research and development expensed		$ 5,320	$ 5,320
DOSE Medical Corporation
Acquisition of IOP Sensor System
Cash payments for the acquisition of certain assets of related party				$ 15,000
Maximum period of support under transition services agreement				3 years
Purchase Agreement for an IOP System | DOSE Medical Corporation
Acquisition of IOP Sensor System
Cash payments for the acquisition of certain assets of related party	$ 5,500
Maximum performance-based consideration	9,500
In-process research and development expensed	5,300
Capitalized fixed assets	$ 200

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Summary (Details) $ / shares in Units, shares in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017USD ($)$ / shares	Sep. 30, 2017USD ($)$ / shares	Jun. 30, 2017USD ($)$ / shares	Mar. 31, 2017USD ($)$ / shares	Dec. 31, 2016USD ($)$ / shares	Sep. 30, 2016USD ($)$ / shares	Jun. 30, 2016USD ($)$ / shares	Mar. 31, 2016USD ($)$ / shares	Dec. 31, 2018	Dec. 31, 2017USD ($)item$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares
Foreign Currency Translation
Foreign currency translation (loss) gain										$ 1,115,000	$ (542,000)	$ (155,000)
Foreign currency translation adjustments											500,000	200,000
Foreign currency transaction realized gain (loss)										100,000	(200,000)	(100,000)
Foreign currency transaction unrealized gain (loss)										951,000	(368,000)	(192,000)
Trading Securities
Trading securities	$ 0				$ 0					0	0	0
Accounts Receivable
Allowance for bad debts	592,000				495,000					592,000	495,000	100,000
Sales return reserve										300,000	200,000	100,000
Long Lived Assets
Long-lived asset impairment										$ 0	14,000	0
Intangible Assets
Number of international distributors | item										3
Revenue Recognition
Warranty period from date of shipment										1 year
Advertising Costs
Advertising Costs										$ 2,100,000	1,600,000	800,000
Income Taxes
Statutory rate of tax expense (as a percent)									21.00%	34.00%
Income tax rate for determining deferred tax assets and liabilities (as a percent)										21.00%
Deferred tax assets from Tax Cuts and Jobs Act of 2017	25,200,000									$ 25,200,000
Numerator:
Net income (loss) attributable to Glaukos Corporation - basic	$ 1,006,000	$ 1,325,000	$ (3,301,000)	$ 878,000	$ 134,000	$ 1,159,000	$ 2,332,000	$ 897,000		$ (92,000)	$ 4,522,000	$ (37,241,000)
Denominator:
Weighted average number of common shares outstanding - basic | shares										34,381	32,928	17,474
Common stock equivalents from outstanding common stock options | shares											3,514
Common stock equivalents for ESPP | shares											16
Common stock equivalents from outstanding common stock warrants | shares											1
Weighted average number of common shares outstanding - diluted | shares										34,381	36,459	17,474
Basic net (loss) income per share (in dollars per share) | $ / shares	$ 0.03	$ 0.04	$ (0.10)	$ 0.03	$ 0	$ 0.03	$ 0.07	$ 0.03		$ 0	$ 0.14	$ (2.13)
Diluted net (loss) income per share (in dollars per share) | $ / shares	$ 0.03	$ 0.04	$ (0.10)	$ 0.02	$ 0	$ 0.03	$ 0.06	$ 0.03		$ 0	$ 0.12	$ (2.13)
Minimum
Long Lived Assets
Estimated useful lives of assets										3 years
Maximum
Long Lived Assets
Estimated useful lives of assets										5 years

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Anti-dilutive securities
Anti-dilutive securities excluded from computation of earnings per share	5,717	1,099	5,796
Stock options
Anti-dilutive securities
Anti-dilutive securities excluded from computation of earnings per share	5,689	1,099	5,701
ESPP
Anti-dilutive securities
Anti-dilutive securities excluded from computation of earnings per share	28		89
Common Stock Warrants
Anti-dilutive securities
Anti-dilutive securities excluded from computation of earnings per share			6

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016
Recent Accounting Pronouncements
Deferred tax assets	$ 65,972		$ 72,268
Deferred tax valuation allowance	$ 65,695		$ 72,268
ASU No. 2016-09 Compensation - Stock Compensation
Recent Accounting Pronouncements
Deferred tax assets		$ 13,100
Deferred tax valuation allowance		$ 13,100

Balance Sheet Details - Short-T

Balance Sheet Details - Short-Term Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Short-term investments
Amortized cost	$ 94,723	$ 89,328
Unrealized gains	7	26
Unrealized losses	(224)	(86)
Estimated fair value	94,506	89,268
U.S. Government bonds
Short-term investments
Amortized cost	1,799
Unrealized losses	(17)
Estimated fair value	$ 1,782
U.S. Government bonds | Maximum
Short-term investments
Maturity	2 years
U.S. Government agency bonds
Short-term investments
Amortized cost	$ 2,698	9,535
Unrealized gains		2
Unrealized losses	(17)	(22)
Estimated fair value	$ 2,681	$ 9,515
U.S. Government agency bonds | Minimum
Short-term investments
Maturity		1 year
U.S. Government agency bonds | Maximum
Short-term investments
Maturity	2 years	3 years
Bank certificates of deposit
Short-term investments
Amortized cost	$ 10,300	$ 11,101
Unrealized gains	1	13
Unrealized losses	(3)	(1)
Estimated fair value	$ 10,298	$ 11,113
Bank certificates of deposit | Maximum
Short-term investments
Maturity	1 year	2 years
Commercial paper
Short-term investments
Amortized cost	$ 11,598	$ 17,011
Unrealized gains		1
Unrealized losses	(5)	(2)
Estimated fair value	$ 11,593	$ 17,010
Commercial paper | Maximum
Short-term investments
Maturity	1 year	1 year
Corporate notes
Short-term investments
Amortized cost	$ 51,532	$ 45,178
Unrealized gains	6	7
Unrealized losses	(121)	(61)
Estimated fair value	$ 51,417	$ 45,124
Corporate notes | Maximum
Short-term investments
Maturity	3 years	3 years
Asset-backed securities
Short-term investments
Amortized cost	$ 16,796	$ 6,503
Unrealized gains		3
Unrealized losses	(61)
Estimated fair value	$ 16,735	$ 6,506
Asset-backed securities | Maximum
Short-term investments
Maturity	3 years	2 years

Balance Sheet Details - Other (

Balance Sheet Details - Other (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounts Receivable, Net
Accounts receivable	$ 17,248	$ 14,800
Less allowance for doubtful accounts	(592)	(495)	$ (100)
Accounts receivable, net	16,656	14,305
Inventory
Finished goods	4,225	2,014
Work in process	2,368	2,105
Raw materials	4,629	2,725
Total inventory	11,222	6,844
Accrued Liabilities
Accrued contract payments (see Note 10)	1,033	823
Accrued sales commissions	506	1,641
Accrued clinical study payments	609	1,167
Accrued bonuses	9,106	6,122
Accrued vacation benefits	2,121	1,382
Accrued Employee Stock Purchase Plan liability	1,517	4
Other accrued liabilities	5,557	2,772
Total accrued liabilities	$ 20,449	$ 13,911

Balance Sheet Details - Propert

Balance Sheet Details - Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property and equipment, net
Property and equipment, gross	$ 18,249	$ 12,888
Less accumulated depreciation and amortization	(6,455)	(5,295)
Property and equipment, net	11,794	7,593	$ 2,154
Depreciation and amortization	5,482	4,722	4,267
Buildings
Property and equipment, net
Property and equipment, gross	874	874
Equipment
Property and equipment, net
Property and equipment, gross	8,311	5,342
Furniture and fixtures
Property and equipment, net
Property and equipment, gross	1,382	639
Leasehold improvements
Property and equipment, net
Property and equipment, gross	4,568	3,474
Computer equipment and software
Property and equipment, net
Property and equipment, gross	1,980	1,239
Construction in progress
Property and equipment, net
Property and equipment, gross	1,134	1,320
Property, Plant and Equipment
Property and equipment, net
Depreciation and amortization	$ 2,100	$ 1,100	$ 800

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Hierarchy (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets
Total assets	$ 99,876	$ 89,348
Liabilities
Total liabilities	0	0
Fair Value, Inputs, Level 1
Assets
Total assets	2,370	80
Fair Value, Inputs, Level 2
Assets
Total assets	97,506	89,268
Money market funds
Assets
Total assets	2,370	80
Money market funds | Fair Value, Inputs, Level 1
Assets
Total assets	2,370	80
U.S. Government agency bonds
Assets
Total assets	2,681	9,515
U.S. Government agency bonds | Fair Value, Inputs, Level 2
Assets
Total assets	2,681	9,515
U.S. Government bonds
Assets
Total assets	1,782
U.S. Government bonds | Fair Value, Inputs, Level 2
Assets
Total assets	1,782
Bank certificates of deposit
Assets
Total assets	10,298	11,113
Bank certificates of deposit | Fair Value, Inputs, Level 2
Assets
Total assets	10,298	11,113
Commercial paper.
Assets
Cash equivalents	3,000
Total assets	14,593	17,010
Commercial paper. | Fair Value, Inputs, Level 2
Assets
Total assets	14,593	17,010
Corporate notes
Assets
Total assets	51,417	45,124
Corporate notes | Fair Value, Inputs, Level 2
Assets
Total assets	51,417	45,124
Asset-backed securities
Assets
Total assets	16,735	6,506
Asset-backed securities | Fair Value, Inputs, Level 2
Assets
Total assets	$ 16,735	$ 6,506

Fair Value Measurements - Trans

Fair Value Measurements - Transfers (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements
Amount of transfers of assets and liabilities measured on a recurring basis between Levels 1, 2 and 3 of the fair value hierarchy	$ 0	$ 0

Long-Term Debt and Intangible46

Long-Term Debt and Intangible Assets- Notes Payable (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Nov. 30, 2013	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other disclosures
Useful life/amortization period		60 months	60 months
GMP royalty buyout
Other disclosures
Intangible asset amortization		$ 3.5	$ 3.5	$ 3.5
Buy-out Agreement with GMP | GMP royalty buyout
Other disclosures
Useful life/amortization period	5 years
Notes Payable | GMP Note Parties | Buy-out Agreement with GMP
Other disclosures
Face amount at time of issuance	$ 17.5

Long-term Debt and Intangible47

Long-term Debt and Intangible Assets - Bank Loan Facility (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jul. 31, 2015	Feb. 28, 2015	Dec. 31, 2015
Long-Term Debt
Loss on extinguishment of debt			$ 195,000
Amended Agreement
Long-Term Debt
Repayments of debt	$ 7,000,000
Loss on extinguishment of debt	200,000
Amended Agreement | Senior Secured Term Loan
Long-Term Debt
Face amount at time of issuance		$ 5,000,000
Proceeds from issuance of debt		5,000,000
Loan origination fees recorded as debt discount		41,000
Debt issuance costs		100,000
Amended Agreement | Senior Secured Draw-to-term Loan
Long-Term Debt
Face amount at time of issuance		5,000,000
Gross long-term debt	$ 2,000,000
Amended Agreement | Senior Secured Revolving Credit Facility
Long-Term Debt
Face amount at time of issuance		$ 8,000,000

Long-Term Debt and Intangible48

Long-Term Debt and Intangible Assets - Summary and Other (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)item	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)item
Composition of intangible assets
Total gross amount	$ 18,024	$ 17,743
Accumulated amortization	(14,877)	(11,176)
Total	$ 3,147	$ 6,567
Useful life/amortization period	60 months	60 months
Number of international distributors | item	3
Estimated amortization expense
2,018	$ 3,100
GMP royalty buyout
Composition of intangible assets
Total gross amount	17,500	$ 17,500
Amortization expense	3,500	3,500	$ 3,500
Non-compete agreements
Composition of intangible assets
Total gross amount	524	243
Amortization expense	$ 300	$ 200
Number of international distributors | item			2
The amount of fair value of the non-compete provisions recorded as intangible asset			$ 200
Non-compete agreements | Minimum
Composition of intangible assets
Useful life/amortization period			1 year
Non-compete agreements | Maximum
Composition of intangible assets
Useful life/amortization period			2 years

Convertible Preferred Stock a49

Convertible Preferred Stock and Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions	Jun. 30, 2015	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2013	Dec. 31, 2017	Dec. 31, 2016	Jun. 29, 2015
Convertible Preferred Stock
Common shares issued upon the conversion of convertible preferred stock (in shares)		21,736,367
Adjustment to additional paid-in-capital, conversion of convertible preferred stock			$ 159.1
Shares outstanding	0		0
Preferred stock, shares authorized						5,000,000	5,000,000
Preferred stock, shares issued						0	0
Repurchase of common stock, shares held in treasury (in shares)					28,000
Common Stock
Convertible Preferred Stock
Common shares issued upon the conversion of convertible preferred stock (in shares)				21,736,000
Shares issued				6,900,000
IPO | Common Stock
Convertible Preferred Stock
Shares issued	6,900,000
Share price (in dollars per share)	$ 18		$ 18
Convertible Preferred Stock
Convertible Preferred Stock
Common shares issued upon the conversion of convertible preferred stock (in shares)	21,700,000
Shares outstanding	0	0	0	0				21,736,367

Stock-Based Compensation - Plan

Stock-Based Compensation - Plan Information (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2017itemshares	Jan. 01, 2017shares
Stock-based compensation
Number of stock plans | item	4
Shares reserved for future issuance	11,481
Expiration period	10 years
Vesting percentage on first anniversary of grant date	25.00%
Remaining vesting period	3 years
2015 Stock Plan
Stock-based compensation
Shares reserved for future issuance		9,500
Employee Stock Purchase Plan 2015
Stock-based compensation
Shares reserved for future issuance		1,500
Maximum employee contributions as a percentage of earnings under the ESPP	15.00%
Purchase price per share expressed as a percentage of the lower of the stock's fair market value on the offering date or purchase date under the ESPP	85.00%
First anniversary | RSU
Stock-based compensation
Vesting (as a percent)	25.00%
Second anniversary | RSU
Stock-based compensation
Vesting (as a percent)	25.00%
Third anniversary | RSU
Stock-based compensation
Vesting (as a percent)	25.00%
Fourth anniversary | RSU
Stock-based compensation
Vesting (as a percent)	25.00%

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2015	Jul. 31, 2014	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Unvested options
Period of time, from termination date, that unvested shares issued to an employee from early exercise of stock options can be repurchased by the Company			90 days
Unvested options exercised (in shares)			0	0	337
Unvested shares subject to repurchase right (in shares)			27	977
Liability related to share-based compensation			$ 0	$ 4,000
Employee stock options
Weighted Average Exercise Price
Granted (in dollars per share)			$ 43.85	$ 21.24	$ 17.79
Nonemployee stock option
Number of Shares Underlying Options
Granted (in shares)			0
2001 Stock Plan, 2011 Stock Plan and 2015 Stock Plan
Number of Shares Underlying Options
Outstanding at beginning of period (in shares)			5,911,000	5,701,000	5,657,000
Granted (in shares)			1,877,000	1,979,000	1,139,000
Exercised (in shares)			(639,000)	(1,660,000)	(1,022,000)
Canceled/forfeited/expired (in shares)			(123,000)	(109,000)	(73,000)
Outstanding at end of period (in shares)			7,026,000	5,911,000	5,701,000	5,657,000
Vested and expected to vest at end of period (in shares)			6,893,000
Exercisable at end of period (in shares)			3,687,000
Weighted Average Exercise Price
Outstanding at beginning of period (in dollars per share)			$ 12.59	$ 7.10	$ 3.93
Granted (in dollars per share)			43.85	21.24	18.07
Exercised (in dollars per share)			5.76	3.65	1.70
Canceled/forfeited/expired (in dollars per share)			23.79	20	6.56
Outstanding at end of period (in dollars per share)			21.36	$ 12.59	$ 7.10	$ 3.93
Vested and expected to vest at end of period (in dollars per share)			21.13
Exercisable at end of period (in dollars per share)			$ 10.58
Additional disclosures
Weighted Average Remaining Contractual Life			7 years 3 months 18 days	7 years 3 months 18 days	6 years 8 months 12 days	6 years 3 months 18 days
Weighted Average Remaining Contractual Life, Vested and expected to vest at end of period			7 years 2 months 12 days
Weighted Average Remaining Contractual Life, Exercisable at end of period			5 years 10 months 24 days
Outstanding, Aggregate Intrinsic Value			$ 69,555,000	$ 129,591,000	$ 102,390,000	$ 16,131,000
Exercised, Aggregate Intrinsic Value			22,105,000	$ 42,458,000	$ 9,174,000
Vested and expected to vest, Aggregate Intrinsic Value			69,080,000
Exercisable, Aggregate Intrinsic Value			$ 57,987,000
Vesting based on performance | Stock options
Unvested options
Cumulative compensation costs	$ 3,800,000
Vesting period			4 years
Number of Shares Underlying Options
Granted (in shares)		1,200,000
Non Employee
Number of Shares Underlying Options
Exercisable at end of period (in shares)			891,400

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units (Details) - RSU shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Number of shares
Granted (in shares)	173
Vested (in shares)	0
Unvested at end of period (in shares)	173
Weighted average grant date fair value
Granted (in dollar per share) | $ / shares	$ 39.10
Unvested at end of period (in dollar per share) | $ / shares	$ 39.10

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value Assumptions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock-based compensation
Unamortized stock-based compensation expense not yet recognized	$ 49,500,000
Stock-based awards to employees - weighted average assumptions used to estimate fair value of options granted
Stock-based compensation cost capitalized	$ 100,000	$ 100,000	$ 43,000
Minimum | Non Employee
Stock-based awards to employees - weighted average assumptions used to estimate fair value of options granted
Exercise price (in dollars per share)	$ 0.25
Maximum | Non Employee
Stock-based awards to employees - weighted average assumptions used to estimate fair value of options granted
Exercise price (in dollars per share)	$ 25.91
RSU
Stock-based compensation
Unamortized stock-based compensation expense not yet recognized	$ 5,600,000
Options remaining vesting period	4 years
Weighted average period of recognition	3 years 6 months
Stock options
Stock-based compensation
Weighted average estimated grant date fair value (per share)	$ 20.62	$ 10.81	$ 9.77
Unamortized stock-based compensation expense not yet recognized	$ 43,900,000
Options remaining vesting period	4 years
Weighted average period of recognition	2 years 8 months 12 days
Fair value of stock options vested	$ 12,900,000	$ 5,700,000
Employee stock options
Stock-based awards to employees - weighted average assumptions used to estimate fair value of options granted
Risk-free interest rate (as a percent)	2.13%	1.59%	1.77%
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%
Expected volatility rate (as a percent)	46.50%	52.90%	56.00%
Expected term	6 years 15 days	6 years 15 days	6 years 26 days
Weighted-average exercise price of options granted (in dollars per share)	$ 43.85	$ 21.24	$ 17.79

Stock-Based Compensation - Allo

Stock-Based Compensation - Allocation of Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Allocation of stock-based compensation
Stock-based compensation expense	$ 17,592	$ 8,786	$ 7,889
Tax benefit related to stock-based compensation	5,400	9,900	500
Cost of sales
Allocation of stock-based compensation
Stock-based compensation expense	597	233	251
Selling, general and administrative
Allocation of stock-based compensation
Stock-based compensation expense	13,006	6,475	5,773
Research and development
Allocation of stock-based compensation
Stock-based compensation expense	3,989	2,078	1,865
Non Employee
Allocation of stock-based compensation
Stock-based compensation expense	$ 500	$ 800	$ 1,100

Stock-Based Compensation - Shar

Stock-Based Compensation - Shares Reserved for Future Issuance (Details) - shares shares in Thousands	Dec. 31, 2017	Jan. 01, 2017
Common Stock Reserved for Future Issuance
Total	11,481
2001 Stock Plan
Common Stock Reserved for Future Issuance
Stock options issued and outstanding (in shares)	811
2011 Stock Plan
Common Stock Reserved for Future Issuance
Stock options issued and outstanding (in shares)	2,001
2015 Stock Plan
Common Stock Reserved for Future Issuance
Stock options issued and outstanding (in shares)	4,388
Authorized for future stock awards or option grants (in shares)	3,443
Total		9,500
Employee Stock Purchase Plan 2015
Common Stock Reserved for Future Issuance
Authorized for future stock awards or option grants (in shares)	838
Total		1,500

Income Taxes - Provision, Recon

Income Taxes - Provision, Reconciliation and Deferred Taxes (Details) - USD ($)	3 Months Ended						12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
United States and foreign loss before income taxes:
United States							$ 12,543,000	$ 12,214,000	$ (36,750,000)
Foreign							(12,542,000)	(7,649,000)	(1,538,000)
Income (loss) before taxes							1,000	4,565,000	(38,288,000)
Current:
Federal							235,000	(28,000)
State							93,000	71,000	33,000
Total current income tax provision							328,000	43,000	33,000
Deferred:
Federal							(235,000)
Total deferred income tax provision							(235,000)
Provision for income taxes	$ (37,000)	$ 53,000	$ 22,000	$ 55,000	$ (97,000)	$ 140,000	93,000	43,000	33,000
Tax provision for noncontrolling interest									0
Reconciliations of the U.S. federal statutory tax rate to the combined effective tax rate
Statutory rate of tax expense								1,552,000	(13,018,000)
State income taxes, net of federal benefit							(17,000)	530,000	(1,347,000)
Permanent and other items							(5,199,000)	789,000	1,307,000
Deconsolidation of DOSE									4,558,000
Nondeductible offering costs								7,000
Research credits							(2,215,000)	(1,945,000)	(1,745,000)
Uncertain tax positions							1,108,000	940,000	865,000
Change in tax rate							1,013,000	1,337,000	68,000
Tax Cuts and Jobs Act							25,216,000
Valuation allowance							(19,813,000)	(3,167,000)	9,345,000
Provision for income taxes	(37,000)	$ 53,000	$ 22,000	$ 55,000	(97,000)	$ 140,000	93,000	43,000	$ 33,000
Components of deferred tax assets
Net operating loss carryforwards	37,571,000				41,144,000		37,571,000	41,144,000
Tax credits	6,713,000				4,913,000		6,713,000	4,913,000
Depreciation and amortization	10,765,000				16,748,000		10,765,000	16,748,000
Stock-based compensation	7,184,000				5,310,000		7,184,000	5,310,000
Reserves and accruals	3,739,000				3,920,000		3,739,000	3,920,000
Other, net					233,000			233,000
Total deferred tax assets	65,972,000				72,268,000		65,972,000	72,268,000
Other, net	(42,000)						(42,000)
Valuation allowance	(65,695,000)				$ (72,268,000)		(65,695,000)	$ (72,268,000)
Net deferred tax assets	$ 235,000						235,000
Net increase in valuation allowance							$ (6,600,000)

Income Taxes - Net Operating Lo

Income Taxes - Net Operating Loss Carryforwards (Details) $ in Millions	Dec. 31, 2017USD ($)
Federal
Net operating loss carryforwards
Net operating loss carryforwards	$ 125.7
State
Net operating loss carryforwards
Net operating loss carryforwards	94.2
Foreign
Net operating loss carryforwards
Net operating loss carryforwards	$ 18

Income Taxes - Tax Credit Carry

Income Taxes - Tax Credit Carryforwards (Details) - Research and development credit carryforward $ in Millions	Dec. 31, 2017USD ($)
Federal
Tax credit carryforwards
Tax credit carryforwards	$ 7.5
State
Tax credit carryforwards
Tax credit carryforwards	$ 7

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Unrecognized tax benefits
Tax Benefits as a result of annul limitations under section 382		$ 100
Balance at beginning of the year	$ 7,227	5,947	$ 4,848	$ 4,066
Reductions for tax positions - prior years			(49)	(284)
Additions for tax positions - current year		1,280	1,148	1,066
Balance at end of the year		7,227	5,947	4,848
Accrued interest and penalties associated with uncertain tax positions		$ 0	0	$ 0
Unrepatriated foreign earnings
Unrecorded income taxes associated with unrepatriated foreign earnings			$ 0
Income Taxes
Statutory rate of tax expense (as a percent)	21.00%	34.00%
Income tax rate for determining deferred tax assets and liabilities (as a percent)		21.00%
Deferred tax assets from Tax Cuts and Jobs Act of 2017		$ 25,200

Employee Benefits (Details)

Employee Benefits (Details) - USD ($)	Jan. 01, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Benefits
Maximum annual contribution per employee (as a percent)		100.00%
Maximum annual contributions per employee age 50 or less		$ 18,000	$ 18,000
Maximum annual contributions per employee over the age of 50		24,000	24,000
Employee contributions		1,000,000	$ 0	$ 0
Employer matching percentage	50.00%
The maximum employer matching contribution percent	6.00%
Defined contribution plan employers matching contribution vesting period	3 years
Deferred compensation plan
Deferred compensation plan liability		600,000
Deferred compensation plan assets		$ 700,000

Commitments and Contingencies -

Commitments and Contingencies - Leases (Details)	Jan. 01, 2017USD ($)	Dec. 31, 2017USD ($)ft²item	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Operating Leases
Rent expense		$ 1,500,000	$ 1,100,000	$ 600,000
Future minimum lease payments under noncancelable operating leases
2,018		1,513,000
2,019		1,340,000
2,020		1,278,000
2,021		1,251,000
Total future minimum payments		5,382,000
Purchase commitments
Purchase commitment due within one year		0
Facilities Leases
Operating Leases
Deferred rent		$ 300,000	$ 200,000
Domestic Office Leases
Operating Leases
The number of adjacent facilities rented | item		2
Number of lease renewal periods | item		2
Optional lease extension term		3 years
Area of leased space | ft²		77,000
Domestic Office Leases | Maximum
Operating Leases
Tenant improvement allowance	$ 264,000
Foreign Subsidiaries Office Leases
Operating Leases
Area of leased space | ft²		14,000

Commitments and Contingencies62

Commitments and Contingencies - Other (Details) - Agreement with the Regents - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 30, 2014
Other commitments
Minimum required annual payment of the commitment obligation, based on net sales of current and future products				$ 0.5
Cost of sales
Other commitments
Commitment obligation payments	$ 3.9	$ 2.8	$ 1.8

Variable Interest Entity (Detai

Variable Interest Entity (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Variable Interest Entity
Cash payments for the acquisition of certain assets of related party													$ 15,000
Charge to other expense relating to deconsolidation of DOSE													25,685
Consolidation of DOSE's results of operations:
Selling, general and administrative		$ 25,963	$ 24,141	$ 24,675	$ 21,481	$ 20,494	$ 16,854	$ 15,120	$ 12,288		$ 96,260	$ 64,756	43,961
Research and development		$ 10,525	$ 9,805	$ 9,633	$ 8,942	$ 7,399	$ 7,807	$ 6,955	$ 7,062		38,905	29,223	25,047
Net loss of DOSE											92	(4,522)	38,321
Consolidation of DOSE's cash flows:
Cash used in operating activities											25,508	12,309	(2,188)
Cash used in investing activities											(11,727)	(26,116)	(85,628)
Cash provided by financing activities											4,667	(1,642)	107,110
Net increase (decrease) in cash and cash equivalents											$ 18,014	$ (15,078)	19,268
DOSE Medical Corporation
Variable Interest Entity
Cash payments for the acquisition of certain assets of related party													$ 15,000
Maximum period of support under transition services agreement													3 years
DOSE Medical Corporation
Variable Interest Entity
Cash payments for the acquisition of certain assets of related party	$ 15,000
Intercompany receivable eliminated	$ 10,900									$ 10,900
Charge to other expense relating to deconsolidation of DOSE										$ 25,700
Maximum period of support under transition services agreement	3 years
DOSE Medical Corporation | Variable Interest Entity, Primary Beneficiary
Consolidation of DOSE's results of operations:
Selling, general and administrative													$ 105
Research and development													890
Interest expense													85
Net loss of DOSE													1,080
Consolidation of DOSE's cash flows:
Cash used in operating activities													(1,134)
Cash used in investing activities													(33)
Cash provided by financing activities													1,158
Net increase (decrease) in cash and cash equivalents													$ (9)

Business Segment Information (D

Business Segment Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)segment	Dec. 31, 2016USD ($)segment	Dec. 31, 2015USD ($)segment
Business Segment Information
Number of reportable segments | segment	1	1	1
Total net sales	$ 159,254	$ 114,397	$ 71,700
Property and equipment, net	11,794	7,593	2,154
Depreciation and amortization	5,482	4,722	4,267
Capital expenditures	6,272	6,549	1,034
United States
Business Segment Information
Total net sales	140,902	104,995	67,698
Property and equipment, net	11,677	7,463	2,012
Depreciation and amortization	5,406	4,654	4,180
Capital expenditures	6,051	6,493	972
International
Business Segment Information
Total net sales	18,352	9,402	4,002
Property and equipment, net	117	130	142
Depreciation and amortization	76	68	87
Capital expenditures	$ 221	$ 56	$ 62

Selected Quarterly Financial 65

Selected Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Selected Quarterly Financial Information (Unaudited)
Net sales	$ 41,650	$ 40,412	$ 41,285	$ 35,907	$ 33,172	$ 29,577	$ 28,556	$ 23,092	$ 159,254	$ 114,397	$ 71,700
Cost of sales	4,630	5,718	5,522	5,180	4,811	3,886	4,359	3,121	21,050	16,177	12,988
Gross profit	37,020	34,694	35,763	30,727	28,361	25,691	24,197	19,971	138,204	98,220	58,712
Operating expenses:
Selling, general and administrative	25,963	24,141	24,675	21,481	20,494	16,854	15,120	12,288	96,260	64,756	43,961
In-process research and development			5,320						5,320
Research and development	10,525	9,805	9,633	8,942	7,399	7,807	6,955	7,062	38,905	29,223	25,047
Total operating expenses	36,488	33,946	39,628	30,423	27,893	24,661	22,075	19,350	140,485	93,979	69,008
(Loss) income from operations	532	748	(3,865)	304	468	1,030	2,122	621	(2,281)	4,241	(10,296)
Total other income (expense), net	437	630	586	629	(431)	269	210	276
Provision for income taxes	(37)	53	22	55	(97)	140			93	43	33
Net (loss) income attributable to Glaukos Corporation stockholders	$ 1,006	$ 1,325	$ (3,301)	$ 878	$ 134	$ 1,159	$ 2,332	$ 897	$ (92)	$ 4,522	$ (37,241)
Basic net (loss) income per share (in dollars per share)	$ 0.03	$ 0.04	$ (0.10)	$ 0.03	$ 0	$ 0.03	$ 0.07	$ 0.03	$ 0	$ 0.14	$ (2.13)
Diluted net (loss) income per share (in dollars per share)	$ 0.03	$ 0.04	$ (0.10)	$ 0.02	$ 0	$ 0.03	$ 0.06	$ 0.03	$ 0	$ 0.12	$ (2.13)